Table 3.

Systemic therapy response of patients who received first-line ICI therapy.

	CN+ST Median (IQR)	ST alone Median (IQR)	P value
Therapy type
Ipilimumab/Nivolumab	33 (70.2)	44 (78.6)
Nivolumab	14 (29.8)	12 (21.4)	0.33
Time to therapy start (median, IQR) d	80 (62–123)	48 (31–77)	<0.0001
Time on therapy (median, IQR) d	84 (63–174.5)	63 (34–85)	0.01
Best response (%)
CR	9 (19.2)	0 (0)
PR	13 (27.7)	15 (26.8)
SD	11 (23.4)	10 (17.9)
PD	9 (19.2)	18 (32.1)
Unknown	5 (10.6)	13 (23.2)	0.003
Grade 3–4 adverse events experienced (%)
Yes	15 (31.9)	13 (23.2)
No	32 (68.1)	43 (76.8)	.32